Better growth outcomes in GH-deficient children treated younger than 2 years of age
Data from two large studies showed that children with growth hormone deficiency (GHD) who began treatment with Norditropin® under 2 years of age had better growth than those first treated at or above 2 years of age, but also had more side effects. This highlights the value of early diagnosis, treatment and close monitoring of children with GHD.
Authors
- Joanne Blair (ORCID: https://orcid.org/0000-0003-3128-5574)
- Bradley S. Miller (ORCID: https://orcid.org/0000-0003-3663-5473)
- Tilman Rohrer (ORCID: https://orcid.org/0000-0001-9516-7863)
- Primož Kotnik (ORCID: https://orcid.org/0000-0001-9570-1130)
- Alberto Pietropoli (ORCID: https://orcid.org/0000-0003-0353-4334)
- Nicky Kelepouris (ORCID: https://orcid.org/0000-0003-2445-2338)
- Michel Polak
- Anne Helene Olsen
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Fairview Health Services (US)
- Novo Nordisk (Denmark) (DK)
- Ljubljana University Medical Centre (SI)
- Alder Hey Children's NHS Foundation Trust (GB)
- Novo Nordisk (United States) (US)
- Novo Nordisk (Switzerland) (CH)
- Institut des Maladies Génétiques Imagine (FR)
- University of Minnesota Children's Hospital (US)
- Saarland University (DE)
Publication Details
- Journal
- Endocrine Connections
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1530/ec-25-0493
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00